The most important financial indicators for the company New Pharma Srl - Unique Identification Number 23688007:
sales in 2023 was
705.496
euro, registering a net profit of
82.125
euro and having an average number of
6
employees.
Firma isi desfasoara activitatea in domeniul Comert cu amanuntul al produselor farmaceutice, in magazine specializate having the NACE code 4773.
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity. The data show the company's evolution during this period, highlighting any increases or potential decreases recorded.
In the last year of activity, the sales increased by 10.5%, from 640.339 euro in the year 2022, to 705.496 euro in 2023.
The Net Profit decreased by -3.718 euro, from 86.103 euro in 2022, to 82.125 in the last year.
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
Debts, Equity, Inventories, Receivables, Accounts, Assets -
New Pharma Srl - CUI 23688007
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Fixed Assets
10.088
9.720
9.259
23.120
19.375
15.767
12.749
8.948
5.894
1.846
Current Assets
181.309
189.993
139.386
162.892
181.476
218.159
234.677
222.975
189.378
211.413
Inventories
97.200
99.258
82.899
101.458
97.397
141.382
159.492
147.768
123.889
141.283
Receivables
57.910
43.523
21.199
58.630
57.451
44.881
58.844
63.285
58.639
60.547
Cash
26.200
47.211
35.288
2.805
26.627
31.897
16.340
11.922
6.851
9.582
Shareholders Funds
118.236
92.596
56.586
83.603
188.048
219.813
231.621
218.799
179.859
194.724
Social Capital
45
45
45
44
43
42
41
40
41
40
Debts
73.162
107.116
92.059
102.409
12.803
14.114
15.805
13.124
15.414
18.534
Income in Advance
0
0
0
0
0
0
0
0
0
0
Exchange rate - RON
4.9465
4.9315
4.9468
4.8371
4.7454
4.6535
4.5681
4.4908
4.445
4.4821
Main CAEN
"4773 - 4773"
CAEN Financial Year
4773
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
211.413 euro in 2023 which includes Inventories of
141.283 euro, Receivables of
60.547 euro and cash availability of
9.582 euro.
The company's Equity was valued at
194.724 euro, while total Liabilities amounted to
18.534 euro.
Equity increased by 15.411 euro, from 179.859 euro in 2022, to 194.724 in 2023.
Activate the Financial Reports subscription with unlimited access and check the evolution and current financial situation of any company.
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Subscription cost is per user. You can pay simultaneously up to 10 users.
RisCo Subscriptions offer the greatest flexibility in choosing the best services according to the needs of each user. These are structured into categories based on the type of service desired, as well as on different service contract periods: monthly, semi-annually, and annually. Check out the subscription offer for the best choices!
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - New Pharma Srl